Title:
神経細胞の中の新規の非選択性陽イオンチャンネル、および脳腫脹を処置するための方法
Document Type and Number:
Japanese Patent JP2009527579
Kind Code:
A
Abstract:
The present invention is directed to therapeutic compounds, treatment methods, and kits affecting the NCCa-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system, and methods of using same. The NCCa-ATP channel is newly expressed in neural tissue following injury such as ischemia, and is regulated by the sulfonylurea receptor SUR1, being inhibited by sulfonylurea compounds, e.g., glibenclamide and tolbutamide, and opened by diazoxide. Antagonists of the NCCa-ATP channel, including SUR1 antagonists, are useful in the prevention, diminution, and treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury. Agonists of the NCCa-ATP channel may be are useful in the treatment neural tissue where damage or destruction of the tissue, such as a gliotic capsule, is desired.
More Like This:
Inventors:
Shimmered, J., Mark
Chen, Minqui
Chen, Minqui
Application Number:
JP2008556507A
Publication Date:
July 30, 2009
Filing Date:
February 19, 2007
Export Citation:
Assignee:
University of Maryland Baltimore
International Classes:
A61K31/64; A61K9/08; A61K31/00; A61K31/175; A61K31/426; A61K31/4439; A61K31/7004; A61P9/10; A61P43/00; B01J19/00; B01L3/00; B29C65/48; B81B1/00; C07K14/705; C12N5/08; G01N27/447; G01N33/68
Attorney, Agent or Firm:
Patent Business Corporation Unias International Patent Office